U.S. Viscosupplementation Market – By Product (Single Injection, 3 Injections, 5 Injections), Source of Origin (Avian, Non-avian), End-use (Hospitals, Ambulatory Surgical Centers) – Forecast (2024 – 2032)

U.S. Viscosupplementation Market Size

U.S. Viscosupplementation Market size in 2023 was valued at USD 1.1 billion and is set to register growth at 7.6% CAGR from 2024 and 2032. Viscosupplementation offers a minimally invasive treatment option for managing the symptoms of osteoarthritis, such as pain and stiffness, thereby driving its adoption. One of the primary drivers is the rising prevalence of osteoarthritis, particularly in the aging population. As people age, the wear and tear on their joints increase, leading to a higher incidence of osteoarthritis.
 

Additionally, the growing preference for non-surgical treatments and the increasing demand for pain management solutions contribute to the market's growth. Viscosupplements are seen as a viable alternative to surgery, providing relief to patients without the risks associated with invasive procedures. Moreover, the advancements in viscosupplementation technology, such as the development of more effective formulations and delivery methods, have further expanded the market's potential.
 

Viscosupplementation is widely used for the treatment of osteoarthritis, especially in the knee joint. It involves injecting a gel-like substance called hyaluronic acid into the joint to provide lubrication and cushioning. Hyaluronic acid is a naturally occurring substance found in the synovial fluid that surrounds joints, acting as a lubricant and shock absorber. In osteoarthritis, the synovial fluid becomes thinner and less effective, leading to increased friction and pain in the joint. By injecting hyaluronic acid directly into the joint, viscosupplementation aims to restore the viscosity and elasticity of the synovial fluid, reducing pain and improving joint function.
 

U.S. Viscosupplementation Market Trends

• The growing geriatric population prone to osteoarthritis is projected to fuel the market growth. The U.S. is experiencing a demographic shift characterized by a rapidly aging population.
   
• For instance, according to the Population Reference Bureau, adults aged 65 and older are projected to increase from 58 million in 2022 to 82 million by 2050, and the share of the 65 and older age group of the total population is projected to grow from 17% in 2022 to 23% by 2050. This demographic trend translates to a larger pool of individuals at risk of developing osteoarthritis, a common age-related condition affecting the joints.
   
• Additionally, conditions such as osteoarthritis are increasingly prevalent in the U.S. population, with clinical studies stating there are over 100 types of arthritis, and osteoarthritis is the most prevalent form of arthritis. Estimates suggest that the disease affects the aging population, with 43% of people suffering from osteoarthritis aged 65 and above.
   
• These elderly individuals are more susceptible to developing osteoarthritis due to factors such as cumulative joint wear and tear, age-related changes in cartilage structure, and reduced joint resilience. Thus, as the geriatric population grows, the prevalence of osteoarthritis is expected to rise, driving demand for effective management strategies, including viscosupplementation.
   

U.S. Viscosupplementation Market Analysis

Based on product, the market is segmented into single injection, 3 injections, and 5 injections. The 3 injections segment dominated the market with 45.6% of market share in 2023 and is anticipated to experience substantial growth at 7.7% during the analysis time.
 

• The three-injection regimen has been supported by robust clinical evidence demonstrating its effectiveness in relieving symptoms of osteoarthritis and improving joint function. Thus, it has been used as a standard treatment protocol for viscosupplementation for many years.
   
• Moreover, the increasing adoption of three injections can be attributed to its optimal treatment duration, flexibility in dosage and administration, convenient treatment schedule, and widespread clinical acceptance. Owing to these factors, this segment is expected to grow significantly in the forthcoming years.

Based on source of origin, the U.S. viscosupplementation market is segmented into avian origin and non-avian origin. The non-avian segment is accounted for significant market share in 2023 and poised to capture the market size of USD 1.6 billion by 2032.
 

• High growth can be attributed to factors such as reduced risk of allergic reactions, ethical and environmental considerations, and the assurance of consistency and purity. Moreover, its broader acceptance in the market contributes to its increasing popularity and adoption in viscosupplementation.
   
• Additionally, as demand for non-animal-derived products continues to rise, non-avian viscosupplements are poised to play an increasingly significant role in meeting patient needs and preferences.
   
• Furthermore, advances in biotechnology and fermentation processes for the production of non-avian products are anticipated to bolster market growth.
   

Based on end-use, the U.S. viscosupplementation market is segmented into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment held majority of market share in 2023 and is predicted to grow at CAGR of 7.5% from 2024 - 2032.
 

• Hospitals offer comprehensive healthcare services, including specialized treatments like viscosupplementation for osteoarthritis. With their broad spectrum of services and resources, hospitals often serve as the primary providers of viscosupplementation therapies, attracting a sizeable patient base seeking orthopedic care.
   
• Additionally, factors such as the rising incidence of osteoarthritis in the U.S., the proliferation of hospitals and clinics, and the availability of advanced medical technologies and equipment further bolster the segment's leading market share.
   

U.S. Viscosupplementation Market Share

The competitive landscape of the market is characterized by a mix of established pharmaceutical companies and emerging players, each striving to capitalize on the growing demand for osteoarthritis treatments. Leading companies such as Anika Therapeutics, Inc., Sanofi SA, Ferring B.V., Bioventus, and Pacira BioSciences, Inc. hold significant market shares due to their extensive product portfolios and strong distribution networks. These companies leverage their research and development capabilities to innovate and introduce advanced formulations and delivery methods, aiming to enhance the efficacy and patient compliance of viscosupplementation therapies.
 

The market is also witnessing increased competition from smaller biotech firms and startups, which are focusing on niche segments and personalized treatment options. Strategic partnerships, mergers and acquisitions, and geographic expansion are common strategies adopted by these players to strengthen their market position and expand their customer base. The intense competition drives continuous improvements in product quality and cost-effectiveness, benefiting healthcare providers and patients alike.
 

U.S. Viscosupplementation Market Companies

Prominent players operating in the U.S. viscosupplementation industry include:

• Anika Therapeutics, Inc
• Avanos Medical, Inc
• Bioventus Inc.
• Ferring Pharmaceutical
• Fidia Farmaceutici S.p.A (Fidia Pharma USA Inc.)
• Lifecore Biomedical, Inc
• Pacira BioSciences, Inc
• Sanofi SA
• Seikagaku Corporation
• Teva Pharmaceutical Industries Ltd.
   

U.S. Viscosupplementation Industry News:

• In November 2022, Anika Therapeutics, Inc. achieved primary endpoint in a Phase III Study for Cingal. This product is intended to provide long lasting pain relief of knee osteoarthritis (OA). The firm is focusing to get the U.S. FDA approval for the Cingal and its launch. This successful trial helped the company to increase their R&D activities and gain a competitive edge over its peers.
   
• In December 2021, Avanos Medical, Inc. entered into a definite agreement to acquire OrthogenRx, Inc., a company specializing in viscosupplementation therapies for knee osteoarthritis (OA) pain. This strategic move aimed to enhance Avanos' chronic pain portfolio by providing a continuum of care treatment options for patients with knee OA, thereby strengthening its business portfolio.
   

The U.S. viscosupplementation market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Single injection
• 3 injections
• 5 injections

Market, By Source of Origin

• Avian origin
• Non-avian origin

Market, By End-use

• Hospitals
• Ambulatory surgical centers
• Other end-users